Logotype for Perspective Therapeutics Inc

Perspective Therapeutics (CATX) Study update summary

Event summary combining transcript, slides, and related documents.

Logotype for Perspective Therapeutics Inc

Study update summary

25 Oct, 2026

Study design

  • Ongoing Phase 1/2a dose-escalation and exploration study in PRRT-naïve, SSTR2-positive NET patients; interim analysis covered 68 patients in Cohorts 1–3, treated with up to four doses of 2.5, 5.0 or 6.0 mCi.

  • Cohort 4 is enrolling with a frontloaded 6/5/5/4 mCi regimen, described as a modified 20 mCi approach.

  • Data cutoff was 10 Sep 2026; analyses were interim and investigator-assessed, with shorter follow-up in Cohort 3 than Cohort 2.

Clinical activity

  • Investigator-assessed ORR, including unconfirmed responses, was 32.6% in Cohort 2 (5.0 mCi; 15/46) and 50.0% in Cohort 3 (6.0 mCi; 10/20); confirmed PR rates were 30.4% and 30.0%, respectively.

  • DCR was 89.1% in Cohort 2 and 95.0% in Cohort 3; among GEP-NET patients with SSTR2 expression in all target lesions, ORR was 36.8% in Cohort 2 and 47.1% in Cohort 3.

  • Across Cohorts 1–3, estimated PFS was 71.9% at 18 months (95% CI 58.3–81.8), 74% at 12 months and 86% at 6 months; Cohort 2 PFS was 68.9% at 18 months.

  • Cohort 3 responses were higher at early assessments; responses were observed as late as 60 weeks, and tumor response and PFS follow-up continue to mature.

Safety and tolerability

  • No dose-limiting toxicities, Grade 4 or 5 TEAEs, treatment-related serious AEs or treatment-related discontinuations; no dysphagia, clinically significant myelosuppression or myelodysplastic syndrome was reported.

  • Grade 3 TEAEs occurred in 20/68 patients (29%); Grade 3 acute kidney injury occurred in 2 patients (2.9%). Investigators assessed one case as unlikely related and one as possibly related; one resolved and one was ongoing.

  • Common TEAEs included alopecia (67.6%), fatigue (66.2%), nausea (64.7%) and diarrhoea (42.6%); alopecia was usually mild and reversible.

  • Low-grade thrombocytopenia and transient leukopenia were observed; blood-cell counts generally recovered within one treatment cycle.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Perspective Therapeutics